• Does dietary caffeine interfere with antinociception by othe

  2024-06-26

  

  (8) Does dietary caffeine interfere with antinociception by other modalities that alter pain (TENS, exercise, joint mobilization, water immersion therapy)? Caffeine and/or A1R antagonists inhibit antinociception by each of these modalities in preclinical studies, such that there is potential for int

• monoamine transporter Previous studies have demonstrated the

  2024-06-26

  

  Previous studies have demonstrated the presence of soluble NTPDases, 5′-nucleotidase and adenosine deaminase in rat blood serum as well as in human blood (Doleski et al., 2016; Oses et al., 2004; Yegutkin, 1997; Yegutkin et al., 2007). In addition, our earlier reports have shown that these membrane-

• br The MIR The MIR is defined by the ability

  2024-06-26

  

  The MIR The MIR is defined by the ability of a single rat mAb to muscle or electric organ AChRs, typically mAb 35, to block binding of half or more of autoantibodies in human MG or EAMG [44], [45], [46]. Antibodies to the MIR are pathologically significant because they exhibit all the major patho

• br Methods br Results and discussion br Conclusions br Ackno

  2024-06-26

  

  Methods Results and discussion Conclusions Acknowledgements The authors thank Dr. Francois Alhenc-Gelas (then INSERM U367, Paris, France), who kindly provided the plasmid for truncated soluble recombinant human ACE – WTΔ, Dr. Elena Arablinskaya (Institute of Phtiziopulmonology, Moscow, R

• hydroxydopamine OHDA is a selective catecholaminergic neurot

  2024-06-26

  

  6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin mainly used to generate lesions in the nigrostriatal pathway in rats (Ungerstedt, 1968). The most common use of 6-OHDA is via unilateral injection into the rat medial forebrain bundle (MFB). DA depletion, nigral DA cell loss, and

• The central problem in amnesia developing

  2024-06-26

  

  The central problem in amnesia developing following impairment of long-term memory consolidation or reconsolidation is a question of the underlying mechanisms, whether it is caused by impairment of retrieval or memory storage mechanisms [3,8,9,[15], [16], [17], [18]]. To answer this question, severa

• The following are the supplementary data related to this

  2024-06-26

  

  The following are the supplementary data related to this article. Funding Work in Dr. Rosell's laboratory is partially supported by a grant from La Caixa Foundation, and an Instituto de Salud Carlos III grant (RESPONSE, PIE16/00011). Work in Dr. Cao's laboratory is partially supported by the Maj

• Additionally we used the predicted Cyp a b amino acid

  2024-06-26

  

  Additionally, we used the predicted Cyp19a1b amino AM966 sale sequence from a number of bony fish species to infer their genetic relatedness and found that R. quelen occupies an ancient position within the Siluriformes group. A phylogenetic tree was constructed and it included both full-length and

• br Conclusions br Acknowledgements We would like to thank

  2024-06-26

  

  Conclusions Acknowledgements We would like to thank the members of the Bergmann lab for fruitful discussions in the course of this work. This work was supported by the National Institute of General Medical Sciences (NIGMS) under award number R35 GM118330. The content is solely the responsibili

• Various antiangiogenic drugs have been analyzed over the las

  2024-06-26

  

  Various antiangiogenic drugs have been analyzed over the last few years; noteworthy, bevacizumab, a monoclonal antibody against VEGF-A, alone or in combination with cytotoxic agents showed interesting results in terms of radiographic response rates and progression-free survival in initial phase 2 st

• Of the cardiovascular studies involving

  2024-06-26

  

  Of the cardiovascular studies involving ARBs, 3 reported renal outcomes. In the Losartan Intervention For Endpoint study, albuminuria was observed less frequently in the losartan than in the atenolol arm (7% vs. 13%; p=0.002) (5). In the Candesartan Antihypertensive Survival Evaluation in Japan tria

• The major phase trial NCT enrolled participants

  2024-06-26

  

  The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef

• Not all secondary metabolites or natural products can

  2024-06-26

  

  Not all secondary metabolites or natural products can be fully synthesized due to their very complex structures that are too difficult and expensive on industrial scale. Hence, there is an urgent need to search for alternative remedies as naturally occurring biologically active secondary metabolites

• However relatively little information is available concernin

  2024-06-25

  

  However, relatively little information is available concerning the biochemical properties and other features of such enzymes in Taeniid species. In the current report, a M17 leucine aminopeptidase gene of T. pisiformis (TpLAP) was cloned and expressed, and its enzymatic activity, biochemical propert

• and LO are members of the

  2024-06-25

  

  5- and 12/15-LO are members of the lipoxygenase family that convert arachidonic AZD3514 into lipid mediators such as leukotriene B4 (LTB) and 12()-hydroxyeicosatetraenoic acid (HETE) and 15()-HETE, respectively. Evidence from several in vitro and in vivo studies has shown that activation of the 5-

16019 records 117/1068 page Previous Next First page 上5页 116117118119120 下5页 Last page